Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetRevenue - OtherRevenue - RentalShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Maxcyte (MXCT) Shares Outstanding (2019 - 2026)

Maxcyte has reported Shares Outstanding over the past 7 years, most recently at $106.8 million for Q4 2025.

  • Quarterly Shares Outstanding rose 1.02% to $106.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $106.8 million through Dec 2025, up 1.02% year-over-year, with the annual reading at $106.8 million for FY2025, 1.02% up from the prior year.
  • Shares Outstanding was $106.8 million for Q4 2025 at Maxcyte, roughly flat from $106.6 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $106.8 million in Q4 2025 and troughed at $84.7 million in Q2 2021.
  • The 5-year median for Shares Outstanding is $103.5 million (2023), against an average of $102.8 million.
  • Year-over-year, Shares Outstanding skyrocketed 30.78% in 2021 and then rose 1.02% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $101.2 million in 2021, then grew by 1.18% to $102.4 million in 2022, then increased by 1.53% to $104.0 million in 2023, then rose by 1.68% to $105.7 million in 2024, then grew by 1.02% to $106.8 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Shares Outstanding are $106.8 million (Q4 2025), $106.6 million (Q3 2025), and $106.6 million (Q2 2025).